Press releases

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Resolution 360™ Clip, a novel technology designed to improve hemostatic clipping by providing physicians controlled...

Boston Scientific Corporation (NYSE: BSX) announced today that Professor Ian Meredith AM will join the company as executive vice president and global chief medical officer in January 2017. In his...

Boston Scientific (NYSE: BSX) and EndoChoice Holdings, Inc. (NYSE: GI) today announced the companies have entered into a definitive agreement under which Boston Scientific has agreed to acquire...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology. The...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's guidance range for the quarter of $2.010 to...

Addition of leading radiofrequency ablation company expands therapeutic options for patients with chronic pain

CEO Mike Mahoney welcomes Fujimori as a business leader with “significant insights on how large companies plan, execute and compete globally.”

Studies show that treatment is less costly and has lower hospital re-admissions

Accelerates momentum to bring differentiated value to patients and health care systems

Full-body MRI access expands spinal cord stimulation offering and brings customized therapy to more patients suffering from chronic pain

Late-breaker data presented at HRS scientific sessions is most extensive post-market study for S-ICD

New catheters and software enhancement expand capabilities of high-definition Rhythmia™ Mapping System

"This strong start enables us to raise our outlook for the year,” said Boston Scientific CEO Mike Mahoney

FDA approval includes ACCOLADE™ MRI and ESSENTIO™ MRI pacemakers and INGEVITY™ MRI pacing leads

European approval granted for third-generation system and all previously implanted, second-generation systems

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the AXIOS™ Stent and Electrocautery Enhanced Delivery System to help physicians manage two serious complications from...

Two organizations to share intellectual property and stimulate the rapid development of medical devices to address unmet clinical needs

FDA approval granted on the heels of CE Mark for the IntellaTip MiFi™ open-irrigated catheter

ACUITY™ X4 Quadripolar Left Ventricular Leads to be used in trial pursuing MRI labeling for cardiac defibrillation and resynchronization systems

First polymer-based, drug-eluting stent designed to treat peripheral lesions above the knee approved in Europe

CMS will cover percutaneous LAAC therapy for Medicare beneficiaries consistent with the FDA label when specific conditions are met

"Our accomplishments in 2015 demonstrate our continued momentum,” said Boston Scientific CEO Mike Mahoney

Bronchial thermoplasty (BT) delivered by the ALAIR™ System offers proven reduction in asthma attacks for adults with severe asthma not well controlled with medication

Care Pathway Transformation solution is designed to enable providers to make better-informed decisions based on patient population insights

Single-use system for stone removal eliminates maintenance, reprocessing and sterilization

Study demonstrates spinal cord stimulation device provided significant decrease in average pain scores sustained over a two-year period

Catheter used to treat deep vein thrombosis to be commercialized in U.S. and Europe

First implants occur in Europe, commencing limited market release

For the second consecutive year, Boston Scientific is named one of the "Best Places to Work for LGBT Equality"

Transaction to expand interventional oncology portfolio with drug-eluting microspheres and spherical embolics

"Our excellent third quarter performance was driven by strong sales and differentiated adjusted operating margin expansion," said CEO Mike Mahoney

Investment continues alliance for percutaneous mitral valve replacement established in 2012

Up to $25,000 in prizes to be awarded to winners

New category of drug-eluting stent approved for U.S. patients

Provides minimally invasive alternative to an esophagectomy

MAJESTIC trial data support strong safety profile with low target lesion revascularization rate

System includes first directional lead with current steering and expanded programming flexibility

Updated labeling allows backwards-compatibility for MRI scans for the industry's longest-lasting ICD and CRT-D systems

U.S. launch underway for therapy designed to treat Peripheral Artery Disease

Men’s health and prostate health acquisition positions Boston Scientific as a urology leader

Strategic alliance to expand Boston Scientific portfolio of remote monitoring solutions

"Our strong performance in the second quarter reflects the consistent execution of our global teams," said Mike Mahoney, CEO of Boston Scientific.

First guidewire designed specifically for TAVI/R now sized for smaller ventricles

First Patients Enrolled in the FAST Feasibility Study

Demonstrates growing clinical acceptance for novel, procedure-based treatment option for severe asthma

Study to evaluate patients implanted with S-ICD for primary prevention of sudden cardiac death in the setting of severely reduced cardiac function

Spinal cord stimulator (SCS) system provided 1.5x better overall pain relief and 2x better low back pain relief than previous generation system

World's smallest 16-contact high-capacity primary cell device expands spinal cord stimulator system (SCS) offering

Compelling results presented at EuroPCR 2015 add to growing body of evidence supporting performance and safety